Cambridge Antibody Technology grants licence to Wyeth
Wyeth has exercised an option to license Cambridge Antibody Technology's (CAT) proprietary antibody phage display libraries for in-house use.
Wyeth has exercised an option to license Cambridge Antibody Technology's (CAT) proprietary antibody phage display libraries for in-house use.
The libraries will support Wyeth's activities in therapeutic antibody drug discovery and development across a broad range of therapeutic areas. This option to license CAT's libraries was granted to Wyeth as part of the collaboration agreement entered into in March 1999.
In return for Wyeth's exercise of the option, CAT will receive an upfront licence fee. Wyeth has a number of exclusive therapeutic and diagnostic antibody product options related to its use of the library which, if exercised, will result in CAT receiving a product licence fee and potential milestone and royalty payments.